Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.

GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...

Liposomal Doxorubicin Market Liposomal Doxorubicin Market Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Liposomal ...

Padma Bhushan awardee folk singer Sharda Sinha left for her heavenly abode on November 5, 2024, after her seven-year-long ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

Data from CARTITUDE-4 supported the U.S. Food and Drug Administration (FDA) and European Commission (EC) approval of CARVYKTI ® earlier this year for the treatment of adult patients with relapsed or ...

Multiple players are exploring whether modalities designed to combat B cell malignancies can be repurposed against lupus, ...